BridgeMD
New treatment option for Peripheral Artery Disease
Official title Telehealth Delivered Home-based Walking for Vets With Peripheral Artery Disease
ClinicalTrials.gov ID: NCT06033924
What this study is testing
- What it's testing
- Walking is beneficial for adults with peripheral arterial disease. Benefits include the ability to walk for longer periods and general well being (quality of life).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 and older
You may be able to join if
- Men and women
- Diagnosis of lower extremity PAD due to atherosclerosis
- Claudication with walking defined as stage 1-3 on the Rutherford Scale
- Medical clearance from the patient's primary care provider or vascular care provider
- Ability to walk at least one city block
You likely can't join if
- Life expectancy of less than six months
- Comorbidities that limit walking to a severe degree (i.e., wheelchair-bound)
- Resident of a nursing home
- Recent enrollment in an exercise program or performing 150 minutes per week or more of exercise
- Planned revascularization or amputation in the next two months
- Recent CVD events (\< 3 months) including stroke/TIA, MI, UA, PCI/CABG
See the full eligibility criteria
- Men and women
- Diagnosis of lower extremity PAD due to atherosclerosis
- Claudication with walking defined as stage 1-3 on the Rutherford Scale
- Medical clearance from the patient's primary care provider or vascular care provider
- Ability to walk at least one city block
- Self-reported sedentary behaviors defined as \< 150 minutes per week of physical activity
- Access to a phone and/or email \& Internet
- Competent to provide informed consent
- Life expectancy of less than six months
- Comorbidities that limit walking to a severe degree (i.e., wheelchair-bound)
- Resident of a nursing home
- Recent enrollment in an exercise program or performing 150 minutes per week or more of exercise
- Planned revascularization or amputation in the next two months
- Recent CVD events (\< 3 months) including stroke/TIA, MI, UA, PCI/CABG
- Unstable cardiac conditions (severe valve disease, NYHA class III-IV heart failure, untreated complex congenital heart disease, or complex arrhythmias)
- Current substance abuse
- Psychiatric disorder which limits the patient's ability to follow the study protocol
- Pregnancy
- Inability to speak and read English
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Palo Alto, California, United States
- Aurora, Colorado, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Palo Alto, California, United States; Aurora, Colorado, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.